Skip to main content

Pharma News

 

Clinical courses

 

Clinical research courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • A new mechanism discovered behind osteoarthritis, may shed light on new therapies

    Researchers in the United States and Japan have discovered a new mechanism that links age-related cartilage tissue stiffening with the repression of a key protein associated with longevity. These findings enhance the understanding of mechanisms that lead to the deterioration of joints that causes osteoarthritis, according to the authors of a new study, published January 10th in Nature Communications.

  • Reducing elevated level of Aldosterone can cure High BP

    Doctors at Queen Mary University of London and Barts Hospital, and Cambridge University Hospital, have led research using a new type of CT scan to light up tiny nodules in a hormone gland and cure high blood pressure by their removal. The nodules are discovered in one-in-twenty people with high blood pressure.

  • Zydus receives approval from the USFDA for Levomilnacipran Capsules

    Zydus Lifesciences Limited’s subsidiary Zydus Pharmaceuticals (USA) Inc. (Zydus) has received tentative approval from the United States Food and Drug Administration (USFDA) to market Levomilnacipran Extended-Release Capsules, 20 mg, 40 mg, 80 mg, and 120 mg (USRLD: Fetzima® Extended-Release Capsules).

  • Lupin Receives approval from USFDA for Dolutegravir and Rilpivirine Tablets

    Global pharma major Lupin Limited announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, to market a generic equivalent of Juluca® Tablets, 50 mg/25 mg of ViiV Healthcare Company.

  • Dr. Reddys Lab acquired trademark rights of product from Pfizer

    Dr. Reddy’s Laboratories Ltd announced that it has acquired the trademark rights of the breast cancer drug PRIMCYV® from Pfizer Products India Pvt Ltd for use in the Indian market.

  • Demand for Indian generic drugs explodes high in China

    The demand for Indian generic drugs has exploded high in China amid the massive COVID surge, with Chinese experts cautioning that fake versions of these drugs are flooding the market.

  • Inflammatory trigger a new clue in Alzheimer’s

    Scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) reported that an inflammatory trigger like one present during viral infections is elevated in Alzheimer’s disease and progressive supranuclear palsy, a rare brain disorder.

    “We have identified a new trigger of brain inflammation in these disorders,” said Elizabeth Ochoa, PhD, study author from UT Health San Antonio. The finding, published in Science Advances, is novel for this reason, she said.

  • Lupin receives FDA nod for Fesoterodine Fumarate Extended-Release Tablets

    Global pharma major Lupin Limited announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, to market a generic equivalent of Toviaz® Extended-Release Tablets, 4 mg and 8 mg, of Pfizer Inc. The product will be manufactured at Lupin’s facility in Goa, India.

  • Protein complexes assemble at the cell membrane in a polarised manner

    Researchers at the Department of Microbiology and Cell Biology (MCB), Indian Institute of Science (IISc), Bengaluru, have deciphered how specific essential protein complexes are distributed across two different regions in the cell membrane. The findings also help us understand how they play a crucial role in coordinating chromosome segregation with cleavage furrow formation during anaphase. An article has been published on the IISc website, making this announcement.

  • How individual bacteria reacts when exposed to different antibiotics

    Bacterial perseverance is a new phenomenon that helps explain how bacteria adapt to survive antibiotic treatments. A group of researchers at Uppsala University have studied how individual bacteria react when exposed to different antibiotics. The result underlines the importance of adhering strictly to antibiotic prescriptions.

    Fighting bacterial diseases is a perpetual arms race between medical scientists developing new therapeutics and the pathogenic bacteria continuously changing their genetic makeup to survive the drugs.

Subscribe to Pharma News